Understanding sun sensitivity in rare porphyria disorders
Part of Digestive system, Genetic & congenital, Hormones & metabolism, Skin clinical trials.
This study tracks how your body reacts to sunlight if you have erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP)—rare genetic conditions that cause painful skin reactions to sun exposure. Researchers will use special devices and daily logs to better understand your symptoms and how light affects your skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 12 or older
- Confirmed diagnosis of EPP or XLP through genetic testing or blood tests showing elevated porphyrin levels
- Currently experiencing symptoms of EPP or XLP
- History of warning signs (tingling, burning) within 45 minutes of sun exposure before skin damage occurs
- Willing to wear a light-measuring device and keep skin covered during the study period
- Able to complete a daily symptom diary and attend study visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This program provides access to bitopertin, an experimental medicine being tested for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)—rare genetic conditions affecting how your body processes heme, a component of blood. The program aims to offer the medication to eligible patients while safety is being studied.
This study follows people with diagnosed porphyria over time to learn more about the condition using past and new lab (biochemical) and genetic (DNA) test results. It may help researchers better understand how porphyrias work and support future care.
This trial tests an oral medication called ciclopirox (ATL-001) to see if it can reduce skin sensitivity to sunlight in adults with CEP. It aims to improve the skin lesions caused by this rare disease.
This trial checks the long-term safety and side effects of an oral medicine called dersimelagon in people with erythropoietic protoporphyria (EPP) or X-linked protoporphyria (XLP). It is mainly for people who have already finished an earlier dersimelagon study and are able to keep coming to clinic visits.
This study builds a large international registry of people with rare, severe pustular psoriasis to help doctors understand the genetics of the condition. You may be asked for information and, if you have eligible family members, DNA testing to learn how the disease runs in families.
This trial tests a compound that affects certain chemicals in your body (purines) to see if it helps people with pseudoxanthoma elasticum (PXE), a rare genetic condition affecting skin, eyes, and blood vessels.
Hear when a new Erythropoietic Protoporphyria (EPP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.